论文部分内容阅读
目的:分析碘-131(131I)标记抗肺癌单克隆抗体1E2在荷Lewis肺癌小鼠体内分布,评估瘤内注射碘-131标记抗肺癌单克隆抗体1E2(131I-1E2)对小鼠Lewis肺癌的生长抑制作用。方法:C57BL/6小鼠右后腿皮下接种Lewis肺癌细胞(LLC)1×106/只,建立荷Lewis肺癌小鼠模型,免疫组化检测Lewis肺癌细胞(LLC)膜上1E2抗原-氨甲酰磷酸合成酶1(CPS1)的表达。131I标记1E2单抗(氯胺T法),检测标记率、放化纯度、放射性比活度。荷瘤小鼠尾静脉注射标记抗体131I-1E218.5MBq,观察其不同时间点在小鼠体内的分布。成瘤后小鼠随机分为4组,分别瘤内注射生理盐水0.1ml(空白对照),1E2单抗3μg(阳性对照),131I-IGg18.5MBq(阴性对照),131I-1E218.5MBq。治疗后每周2次测定肿瘤大小,21天后处死小鼠观察肿瘤组织病理学改变,检测肿瘤体积、重量,计算抑瘤率。结果:1E2抗原-CPS1主要在肿瘤细胞膜表达,131I-1E2标记率为67.73%,放化纯度为95.63%。131I-1E2主要分布在肿瘤组织,治疗后3周试验组肿瘤体积为(0.75±0.15)cm3,重量为(1.60±0.19)g,抑瘤率78.30%,与对照组间比较差异有统计学意义(P<0.01),对照组之间差异无统计学意义(P>0.05)。治疗组与对照组间病理学差异显著。结论:131I-1E2瘤内注射可抑制肿瘤的生长,具有潜在的临床应用价值,有可能成为新的肿瘤治疗靶向药物。
OBJECTIVE: To analyze the distribution of 131I labeled anti-lung cancer monoclonal antibody 1E2 in mice bearing Lewis lung cancer and evaluate the effect of intratumoral injection of iodine-131 labeled anti-lung cancer monoclonal antibody 1E2 (131I-1E2) on Lewis lung cancer in mice Growth inhibition. Methods: Lewis lung carcinoma cells (LLC) were inoculated subcutaneously in the right hind leg of C57BL / 6 mice at a dose of 1 × 106 / mouse to establish a mouse model of Lewis lung carcinoma. Immunohistochemistry was used to detect the 1E2 antigen - carbamyl in Lewis lung carcinoma (LLC) Phosphate synthase 1 (CPS1) expression. 131I labeled 1E2 monoclonal antibody (chloramine T method), detection of labeling rate, radiochemical purity, radioactivity specific activity. The tumor-bearing mice were injected with 131I-1E218.5MBq labeled antibody through the tail vein to observe their distribution in mice at different time points. Tumor-bearing mice were randomly divided into 4 groups, respectively, intratumoral injection of saline 0.1ml (blank control), 1E2 monoclonal antibody 3μg (positive control), 131I-IGg18.5MBq (negative control), 131I-1E218.5MBq. Tumor size was measured twice a week after treatment. After 21 days, the mice were killed to observe the histopathological changes of the tumor, the tumor volume and weight were measured, and the tumor inhibition rate was calculated. Results: The expression of 1E2 antigen-CPS1 was mainly expressed in tumor cell membrane. The labeling rate of 131I-1E2 was 67.73% and the radiochemical purity was 95.63%. The tumor volume of 131I-1E2 was mainly in the tumor tissue. The tumor volume in the experimental group was (0.75 ± 0.15) cm3 and the weight was (1.60 ± 0.19) g and the inhibitory rate was 78.30% at 3 weeks after treatment. There was significant difference between the two groups (P <0.01), there was no significant difference between the control group (P> 0.05). Pathological differences between treatment group and control group were significant. Conclusion: 131I-1E2 intratumoral injection can inhibit tumor growth, has potential clinical value, may become a new drug for the treatment of cancer.